At SLEEP 2026, the sleep medicine specialist at University of Arizona discussed the new American Academy of Sleep Medicine guideline on the use of combination therapy in adults with chronic insomnia. ...

FDA has cleared C2N Diagnostics' PrecivityAD2 blood test for adults 40 years and older with cognitive symptoms, offering fast amyloid and tau insight to guide diagnosis and trials in Alzheimer disease ...

Expert Stephen Salloway, MD, discussed findings from the TRAILBLAZER-ALZ 6 study, highlighting how a stepwise donanemab dosing regimen significantly lowered rates of ARIA in early Alzheimer disease.

Erika Trovato, DO, MS, program director of the Brain Injury Medicine Fellowship at Burke Rehabilitation Hospital, provided clinical advice for trainees and early-career physicians looking to establish ...

Glenn Graham, MD, PhD; and Sharyl Martini, MD, PhD, moderate a discussion with 4 clincial experts to advance specialized clinical care, education and research for Veterans with movement disorders, ...

The absence of symptoms, nonserious classification, and generally stable neurodevelopmental assessments support short-term clinical quiescence, but do not define long-term neurologic risk. Uncertain ...

The FDA has granted Fast Track Designation to safusidenib, an investigational oral, brain-penetrant selective inhibitor of mutant IDH1, for the treatment of patients with IDH1-mutant glioma, according ...

Despite comedians’ assertions to the contrary, sex-associated headaches are not funny. But medications can help relieve or even prevent them. Comedians have long joked about spouses avoiding sex by ...

Dustin Gable, MD, PhD, a pediatric neuromuscular neurologist at Johns Hopkins Medicine, discussed why bulbar dysfunction ...

Michael Levy, MD, PhD, discusses how Aquaporin-4 IgG-seropositive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD) is a rare autoimmune condition affecting the central nervous system.

A coalition of Charcot-Marie Tooth patient groups, clinicians, and pharma companies has published the first consensus framework for designing clinical trials in the disease. A coalition of ...

The PDUFA date moved to November 22, 2026, because CBER accepted a major BLA amendment incorporating additional HOPE-3 follow ...